Drug Trial Radar · NCT04126681
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Last checked: Nov 20, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
144
Actual
Start
Oct 21, 2019
Primary completion
Aug 1, 2024
Study completion Aug 1, 2024
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- Collaborators
- HealthQuest Pharma Inc.
- First posted
- Oct 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors. The efficacy of HQP1351 is determined by evaluating the subjects' event free survival (EFS).
Conditions
- Chronic Myeloid Leukemia, Chronic Phase
Interventions
HQP1351Drug
HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I
Hydroxyurea or Interferon-based therapyDrug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
HomoharringtonineDrug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
Imatinib, Dasatinib or NilotinibDrug
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event free survival (EFS)Time frame: By the end of Cycle 24 (each cycle is 28 days)
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, Gongdong, China
Nanfang hospital of southern medical university
Guangzhou, Guangdong, China
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
The First affiliated hospital of Guangxi Medical University
Nanning, Guangxi, China
Henan Provincial Oncology Hospital
Zhengzhou, Henan, China
Henan Provincial people's Hospital
Zhengzhou, Henan, China
Tongji Hospital medical college Huazhong University of Science and Technology
Wuhan, Hubei, China
Union Hospital medical college Huazhong University of Science and Technology
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Xiangya Hospital Central South University
Changsha, Hunan, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The First affiliated hospital of Nanchang University
Nanchang, Jiangxi, China
First Hospital of Jilin University
Changchun, Jilin, China
The Affiliated hospital of Qingdao University
Qingdao, Shandong, China
Qilu hospital of Shandong University
Jinan, Shangdong, China
Ruijing Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, Zhejiang University School of Medicine(hematology dept)
Hangzhou, Zhejiang, China
The First Affiliated Hospital, Zhejiang University School of Medicine(HSCTdept)
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.